The first implantable neuromodulation system designed to support natural erectile function recovery, following prostate cancer surgery - when nerve damage is most common. Restoring Erectile Nerve Function at the source.
CaverSTIM™ is currently in clinical trials at leading research centers across the world.
Clinical trials are ongoing to validate long-term safety and efficacy, including pilot studies in the U.S. at Johns Hopkins University School of Medicine and in Australia at the Royal Melbourne Hospital
CaverSTIM™ is an investigational device. Safety and efficacy are being evaluated in clinical trials. This device is not approved for commercial use.
Mission: To restore sexual health and quality of life for men facing nerve-related erectile dysfunction, starting with prostate cancer surgery.
Vision: To redefine the standard of care for nerve-related erectile dysfunction, and to expand the use of neuromodulation across urologic conditions caused by disrupted nerve signaling.
Learn About ComphyaEven with nerve-sparing surgery:
Men deserve a restorative solution, beyond disease treatment.
CaverSTIM™ aims to offer that.
Understanding the Challenge
Prostate cancer is one of the most common cancers in men, with over 400,000 prostatectomies performed each year across the U.S. and Europe. For many, the goal beyond survival is quality of life.
The Critical Moment
Even with nerve-sparing robotic techniques, microscopic trauma to the cavernous nerves is often unavoidable. Studies show 60-70% of men experience erectile dysfunction following surgery, and fewer than 1 in 5 recover baseline function.
The Current Reality
Nerve regeneration can take months or years, and for many, it never fully returns. Current options like pills, injections, pumps and prostheses focus on symptom management — not nerve healing. The impact goes beyond the physical: over 50% of men with post-surgical ED experience depression or loss of confidence, and 1 in 3 report a diminished sense of identity.
Reimagining Recovery
CaverSTIM™ is being developed to enable nerve healing from the critical moment - following surgery - when intervention may have the greatest potential to preserve function and improve long-term outcomes.
CaverSTIM™ is an investigational device not approved for commercial use.
Our technology activates the body's own neural pathways, aiming to restore erectile function in a way that feels natural rather than contrived.
Instead of treating symptoms after injury, our focus is on protecting and activating those nerves most at risk from prostatectomy — the cavernous nerves essential to erectile function.
CaverSTIM™ engages nerve pathways during the critical biologic window following surgery — when stimulation may have the greatest impact on long-term recovery.
Designed to fit seamlessly into standard surgical workflows, CaverSTIM™ integrates neuromodulation technology without adding complexity or additional invasive procedures.
Designed to fit easily into existing work flows — helping providers, patients, and payors rethink male sexual health as part of cancer treatment.
Built for seamless surgical adoption
A discreet therapy designed to support natural recovery — not lifelong treatment.
A restorative approach to reduce long-term ED treatment burden
Placed during surgery to align with nerve pathways, no additional procedure needed.
A small, rechargeable unit placed under the skin, programmed by clinicians and tailored to patient needs.
Stimulation begins shortly after surgery, aligning with critical windows for nerve recovery.
Comphya is a Swiss clinical-stage medical device company developing CaverSTIM™, an implantable neuromodulation system intended to support nerve function following radical prostatectomy.
